GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Perseus Proteomics 4882.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

123

+4.24%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

¥135.5m

FY2018FY2026

Net income

−¥718.1m

FY2018FY2026

Free cash flow

−¥662.8m

FY2018FY2026

Shareholders' equity

¥1.22bn

FY2018FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue¥135.5m¥120.4m¥100.4m¥94.2m¥71.9m¥67.9m¥85.8m¥276.0m¥304.0m
Research and development¥573.6m¥594.5m¥616.0m¥494.5m¥308.4m¥313.4m¥713.7m¥244.6m¥135.2m
Operating income−¥745.0m−¥829.7m−¥895.0m−¥697.8m−¥481.5m−¥415.3m−¥812.4m−¥144.8m−¥166.2m
Net income−¥718.1m−¥904.8m−¥1.10bn−¥787.0m−¥599.0m−¥413.2m−¥841.7m−¥163.1m−¥178.3m
Diluted earnings per share-42.00-61.34-74.93-66.78-50.94-35.14-72.03-9.54-10.43

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets¥1.62bn¥1.82bn¥1.69bn¥2.57bn¥3.30bn¥1.12bn¥547.0m¥1.36bn¥1.51bn
Cash and short-term investments¥1.52bn¥1.67bn¥1.54bn¥2.44bn¥3.21bn¥1.07bn¥482.0m¥1.10bn¥1.45bn
Total liabilities¥405.8m¥386.4m¥295.5m¥170.1m¥148.4m¥34.9m¥46.7m¥32.5m¥24.3m
Shareholders' equity¥1.22bn¥1.43bn¥1.40bn¥2.40bn¥3.15bn¥1.08bn¥485.0m¥1.33bn¥1.49bn
Shares outstanding17m15m15m12m12m12m12m17m17m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−¥653.3m−¥719.5m−¥833.9m−¥564.3m−¥476.8m−¥422.8m−¥608.5m−¥329.7m−¥132.4m
Capital spending−¥9.5m−¥75.2m−¥143.0m−¥170.5m−¥33.9m−¥2.8m−¥2.6m−¥15.0m−¥448,000
Free cash flow−¥662.8m−¥794.6m−¥976.9m−¥734.8m−¥510.7m−¥425.7m−¥611.1m−¥344.7m−¥132.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥35.2m¥32.4m¥42.1m¥37.5m¥23.5m¥37.3m¥23.7m¥38.5m
Operating income−¥204.3m−¥171.6m−¥173.6m−¥181.5m−¥218.3m−¥196.3m−¥215.7m−¥193.4m
Net income−¥202.6m−¥170.3m−¥168.4m−¥203.3m−¥176.1m−¥210.3m−¥199.0m−¥276.3m
Diluted earnings per share-11.85-9.96-11.42-13.79-11.94-14.26-13.50-18.74
Cash from operations———————−¥155.0m
Capital spending———————−¥25.0m
Free cash flow———————−¥180.0m
Total assets¥1.67bn¥1.62bn¥1.32bn¥1.46bn¥1.65bn¥1.82bn¥2.00bn¥2.19bn
Cash and short-term investments¥1.59bn¥1.52bn¥1.24bn¥1.39bn¥1.51bn¥1.67bn¥1.88bn¥2.09bn
Shareholders' equity¥1.22bn¥1.22bn¥884.6m¥1.05bn¥1.26bn¥1.43bn¥1.64bn¥1.84bn

Financial ratios

Data as of 21 Oct 2026

FY2026FY2025FY2024FY2023FY2022FY2021
Operating margin-528.5%-749.6%-1098.1%-833.4%-830.1%-611.2%
Net margin-529.9%-751.7%-1100.0%-835.4%-832.8%-608.1%
Return on equity-59.0%-63.2%-79.0%-32.8%-19.0%-38.1%
Return on assets-44.2%-49.7%-65.2%-30.7%-18.1%-36.9%
Free cash flow yield-26.0%-33.2%-38.5%-32.6%-27.6%-24.5%
Revenue growth12.6%19.9%6.6%31.0%5.9%-20.8%
Earnings growth-20.6%-18.1%40.3%31.4%45.0%-50.9%
Current ratio24.58x14.22x12.80x22.63x22.18x31.76x
Debt to equity———0.00x0.00x0.00x
Equity ratio75.0%78.8%82.6%93.4%95.5%96.9%
Interest coverage——-199.45x———
R&D as a share of sales423.3%493.9%613.5%524.9%428.8%461.2%
Buybacks as a share of market value-15.9%-0.1%-25.1%-0.2%0.0%-0.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.9%14.8%—
Operating income2.2%12.4%—
Net income-3.0%11.7%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Price to earnings-3.2-3.6-7.5-9.3-6.2-11.3
Price to sales16.827.482.577.351.368.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.